Interestingly, downregulation of METTL18 in the MDA-MB-231 cells did not reduce the protein level of HER2 (data not shown), implying that METTL18 cannot directly modulate HSP90 by elevating HER2 status and rather lowered HER2 level might settle down the environment of increased level of METTL18 to manage oncogenic status of HER2-negative breast tumor cells. This evidence concerns the gene ERBB2 and breast neoplasm.